No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, vol.61, pp.1715-1740, 2015. ,
,
In-utero ART exposure and the need for pharmacovigilance. The Lancet Global health, vol.6, p.29880311, 2018. ,
Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding, Curr Opin HIV AIDS, vol.12, issue.4, p.28426519, 2017. ,
Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing, Aids, vol.30, issue.8, p.27128333, 2016. ,
Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women. CROI ,
,
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Antimicrob Agents Chemother, vol.59, p.25845873, 2015. ,
Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy, Antimicrob Agents Chemother, issue.6, p.61, 2017. ,
Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model, The Journal of antimicrobial chemotherapy, vol.71, issue.2, pp.480-483, 2016. ,
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. The Lancet Global health, vol.6, p.29880310, 2018. ,
Assessing the risk of dolutegravir for women of childbearing potential. The Lancet Global health, vol.6, p.30049617, 2018. ,
Dolutegravir for HIV: a lesson in pregnancy safety research, Lancet, vol.391, p.2296, 2018. ,
Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs, Eur J Obstet Gynecol Reprod Biol, vol.147, issue.2, p.19773109, 2009. ,
Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model, Am J Obstet Gynecol, vol.198, issue.4, pp.433-434, 2008. ,
Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am J Obstet Gynecol, vol.213, issue.5, pp.710-711, 2015. ,
Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model, Am J Obstet Gynecol, vol.206, issue.1, pp.92-93, 2012. ,
A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways, Clinical pharmacokinetics, 2016. ,
Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy, Am J Obstet Gynecol, vol.210, issue.3, pp.275-276, 2014. ,
Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients, Br J Clin Pharmacol, vol.80, issue.3, p.25819132, 2015. ,
Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model, Aids, vol.32, issue.3, p.29112064, 2018. ,
Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol, vol.195, issue.1, p.16678781, 2006. ,
Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model, Obstetrics and gynecology international, p.726593, 2009. ,
Placental transfer of darunavir in an ex vivo human cotyledon perfusion model, Antimicrob Agents Chemother, vol.58, issue.9, p.24982090, 2014. ,
Flow-dependent transfer of antipyrine in the human placenta in vitro, Reprod Nutr Dev, vol.23, issue.1, p.6221374, 1983. ,
URL : https://hal.archives-ouvertes.fr/hal-00898027
Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am J Obstet Gynecol, vol.114, issue.6, p.4676572, 1972. ,
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression, Antimicrob Agents Chemother, vol.57, issue.3, p.23295922, 2013. ,
Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model, Antimicrob Agents Chemother, vol.59, issue.5, p.25691637, 2015. ,
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, vol.21, issue.10, p.17582235, 2007. ,
Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir, Clinical pharmacokinetics, vol.52, issue.11, p.23824675, 2013. ,
, Dolutegravir, CID = 54726191
Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment, Antimicrob Agents Chemother, vol.59, issue.9, p.26149996, 2015. ,
Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol, vol.195, issue.1, p.16678781, 2006. ,
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob Agents Chemother, vol.60, issue.5, p.26833154, 2016. ,
Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model, Am J Obstet Gynecol, vol.207, issue.6, pp.514-515, 2012. ,
No Perinatal Transmission of HIV-1 in Women Efficiently Treated Since Conception, CROI, 2015. ,
, , p.2015
Tolerance of the newborn to antiretroviral drug exposure in utero, Expert opinion on drug safety, vol.14, issue.5, p.25727366, 2015. ,
Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant in the Room?, J Infect Dis, vol.213, issue.7, p.26265779, 2016. ,